Downgrade Alert for Sucampo Pharmaceuticals (SCMP)
Sucampo Pharmaceuticals (NASDAQ:SCMP) was downgraded from Buy to Neutral at Mizuho today. The stock closed yesterday at $11.72 on volume of 655,000 shares, above average daily volume of 543,000.
Potential upside of 107.2% exists for Sucampo Pharmaceuticals, based on a current level of $11.72 and analysts' average consensus price target of $24.29. Sucampo Pharmaceuticals shares should encounter resistance at the 200-day moving average (MA) of $17.01 and support at the 50-day MA of $11.45.
In the past 52 weeks, Sucampo Pharmaceuticals share prices have been bracketed by a low of $9.59 and a high of $29.67 and closed yesterday at $11.72, 22% above that low price. Over the last five market days, the 200-day moving average (MA) has gone down 1.2% while the 50-day MA has declined 1.8%.
Sucampo Pharmaceuticals, Inc. researches and develops drugs based on protones, which are derived from functional fatty acids. The Company produces a prescription drug for the treatment of chronic idiopathic constipation.
SmarTrend is tracking the current trend status for Sucampo Pharmaceuticals and will alert subscribers who have SCMP in their portfolio or watchlist when shares have changed trend direction.
Keywords: analyst upgrades/downgrades sucampo pharmaceuticals